Inicia sesión Registrate Mi Biblioteca idioma

Idioma

biblioteca idioma abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará la selección de artículos sobre Trastornos del Movimiento clasificados según los 11 tipos establecidos por International Parkinson & Movement Disorder Society.

Corea y enfermedad de Huntington

263 ARTíCULOS , VIENDO DEL 226 AL 240

PUBMED

Stem cells in animal models of Huntington disease: A systematic review.

Colpo GD, Stimming EF, Teixeira AL.

Mol Cell Neurosci. 2019 Jan 24. pii: S1044-7431(18)30391-9. doi: 10.1016/j.mcn.2019.01.006. [Epub ahead of print] Review.

0

0

0

PUBMED

Biological Motion Perception in Huntington's Disease.

Matheis T, Evinger C, Schubert R, Mazzola S, Fels M, Kemper N, Reilmann R, Muratori L.

J Huntingtons Dis. 2019 Apr 22. doi: 10.3233/JHD-180337. [Epub ahead of print]

0

0

0

PUBMED

Effect of Apolipoprotein E Genotypes on Huntington's Disease Phenotypes in a Han Chinese Population.

Li XY, Zhang YB, Xu M, Cheng HR, Dong Y, Ni W, Li HL, Wu ZY.

Neurosci Bull. 2019 Mar 18. doi: 10.1007/s12264-019-00360-1. [Epub ahead of print]

0

0

0

PUBMED

Targeting Huntingtin Expression in Patients with Huntington's Disease.

Tabrizi SJ, Leavitt BR, Landwehrmeyer GB, Wild EJ, Saft C, Barker RA, Blair NF, Craufurd D, Priller J, Rickards H, Rosser A, Kordasiewicz HB, Czech C, Swayze EE, Norris DA, Baumann T, Gerlach I, Schob

N Engl J Med. 2019 May 6. doi: 10.1056/NEJMoa1900907. [Epub ahead of print]

0

0

0

PUBMED

Erucic acid, a nutritional PPARδ-ligand may influence Huntington's disease pathogenesis.

Altinoz MA, Ozpinar A, Ozpinar A, Hacker E.

Metab Brain Dis. 2020 Jan;35(1):1-9. doi: 10.1007/s11011-019-00500-6. Epub 2019 Oct 17. Review.

0

0

0

PUBMED

Olfactory bulb atrophy and caspase activation observed in the BACHD rat models of Huntington disease.

Lessard-Beaudoin M, Yu-Taeger L, Laroche M, Singer E, Riess O, Nguyen HHP, Graham RK.

Neurobiol Dis. 2019 Feb 6;125:219-231. doi: 10.1016/j.nbd.2019.02.002. [Epub ahead of print]

0

0

0

PUBMED

[Application of high-throughput whole genome sequencing and STR typing for the analysis of chorea villus tissue samples from spontaneous abortion].

Zhang J, Wang S, Yang Y, Zhang J, Wu X, Chen C, Yao F, Zhang Y.

Zhonghua Yi Xue Yi Chuan Xue Za Zhi. 2019 Dec 10;36(12):1171-1174. doi: 10.3760/cma.j.issn.1003-9406.2019.12.005. Chinese.

0

0

0

PUBMED

Circadian dysfunction in the Q175 model of Huntington's disease: Network analysis.

Smarr B, Cutler T, Loh DH, Kudo T, Kuljis D, Kriegsfeld L, Ghiani CA, Colwell CS.

J Neurosci Res. 2019 Dec;97(12):1606-1623. doi: 10.1002/jnr.24505. Epub 2019 Jul 29.

0

0

0

PUBMED

Lack of mutant huntingtin in cortical efferents improves behavioral inflexibility and corticostriatal dynamics in Huntington's disease mice.

Estrada-Sánchez AM, Blake CL, Barton SJ, Howe AG, Rebec GV.

J Neurophysiol. 2019 Dec 1;122(6):2621-2629. doi: 10.1152/jn.00777.2018. Epub 2019 Nov 6.

0

0

0

PUBMED

Spatiotemporal gait characteristics of Huntington's disease during dual-task walking.

Radovanović S, Vodopić S, Stanković I, Dragašević-Mišković N, Kostić V.

Int J Neurosci. 2019 Oct 2:1-8. doi: 10.1080/00207454.2019.1667781. [Epub ahead of print]

0

0

0

PUBMED

Efficacy of Cholesterol Nose-to-Brain Delivery for Brain Targeting in Huntington's Disease.

Passoni A, Favagrossa M, Colombo L, Bagnati R, Gobbi M, Diomede L, Birolini G, Di Paolo E, Valenza M, Cattaneo E, Salmona M.

ACS Chem Neurosci. 2020 Feb 5;11(3):367-372. doi: 10.1021/acschemneuro.9b00581. Epub 2020 Jan 7.

0

0

0

PUBMED

Quality Control in Huntington's Disease: a Therapeutic Target.

Rai SN, Singh BK, Rathore AS, Zahra W, Keswani C, Birla H, Singh SS, Dilnashin H, Singh SP.

Neurotox Res. 2019 Oct;36(3):612-626. doi: 10.1007/s12640-019-00087-x. Epub 2019 Jul 11. Review.

0

0

0

PUBMED

Vildagliptin Attenuates Huntington's Disease through Activation of GLP-1 Receptor/PI3K/Akt/BDNF Pathway in 3-Nitropropionic Acid Rat Model.

Sayed NH, Fathy N, Kortam MA, Rabie MA, Mohamed AF, Kamel AS.

Neurotherapeutics. 2020 Jan;17(1):252-268. doi: 10.1007/s13311-019-00805-5.

0

0

0

PUBMED

A Combinatorial Cell and Drug Delivery Strategy for Huntington's Disease Using Pharmacologically Active Microcarriers and RNAi Neuronally-Committed Mesenchymal Stromal Cells.

André EM, Delcroix GJ, Kandalam S, Sindji L, Montero-Menei CN.

Pharmaceutics. 2019 Oct 12;11(10). pii: E526. doi: 10.3390/pharmaceutics11100526.

0

0

0

PUBMED

Rationally designed small molecules targeting toxic CAG repeat RNA that causes Huntington's disease (HD) and spinocerebellar ataxia (SCAs).

Khan E, Biswas S, Mishra SK, Mishra R, Samanta S, Mishra A, Tawani A, Kumar A.

Biochimie. 2019 May 8;163:21-32. doi: 10.1016/j.biochi.2019.05.001. [Epub ahead of print]

0

0

0

Comentarios

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo HONcode Logo WIS

En colaboración con:

Zambon Neuroacademy